Evommune starts Phase 2b trial of EVO756 for migraine prevention
EVMN•Phase 2b trial underway for migraine prevention candidate
Evommune launched a Phase 2b trial of oral MRGPRX2 inhibitor EVO756 for migraine prevention, dosing the first patient.
Top-line results have not been presented; data are expected in 2027.
The study aims to show fewer migraine days in adults with refractory disease, positioning EVO756 as a differentiated oral preventive option.
About 330 patients are being enrolled globally, testing two dose levels against placebo over 12 weeks.
